Acromegaly
Conditions
Brief summary
The purpose of the protocol is to achieve an in-depth understanding of the current satisfaction status of somatostatin analogue (SSA) treatment for acromegaly through patient and physician surveys.
Interventions
None listed
Sponsors
Ipsen
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
For Patients: * Age 18 years or older * Diagnosed with acromegaly * Receiving current SSA injections for acromegaly treatment for at least 3 months * Signed electronic Informed Consent Form (eICF) For Physicians: * Licensed endocrinologists or neurosurgeons * Having prescribed SSAs for at least five patients with acromegaly in the past 6 months * Signed eICF
Exclusion criteria
* Patients will not be included in the survey if they meet any of the following criteria: * Patients who are not able to successfully complete the questionnaire independently * Pregnant patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall patient satisfaction with SSA treatment. | During the whole study period (approximately 3 months). | To be assessed by four levels of satisfaction including very satisfied, satisfied, dissatisfied, and very dissatisfied |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Patient satisfaction with frequency of administration of SSA treatment | During the whole study period (approximately 3 months). | — |
| Patient satisfaction with mode of administration of SSA treatment | During the whole study period (approximately 3 months). | — |
| Patient satisfaction with convenience of administration of SSA treatment | During the whole study period (approximately 3 months). | — |
| Patient satisfaction with injection site reactions of SSA treatment | During the whole study period (approximately 3 months). | — |
| Patient satisfaction with adverse reactions to SSA treatment | During the whole study period (approximately 3 months). | — |
| Physician overall satisfaction with SSA treatment. | During the whole study period (approximately 3 months). | The satisfaction rate is calculated as the proportion of physicians who reported to be satisfied or very satisfied with the prescribed SSA treatment. |
| Physician satisfaction with symptom control of SSA treatment | During the whole study period (approximately 3 months). | — |
| Patient satisfaction with symptom control of SSA treatment | During the whole study period (approximately 3 months). | — |
| Physician satisfaction with mode of administration of SSA treatment | During the whole study period (approximately 3 months). | — |
| Physician satisfaction with convenience of administration of SSA treatment | During the whole study period (approximately 3 months). | — |
| Physician satisfaction with injection site reactions of SSA treatment | During the whole study period (approximately 3 months). | — |
| Physician satisfaction with adverse reactions to SSA treatment | During the whole study period (approximately 3 months). | — |
| Aspects of patient concern before initiating SSA treatment | During the whole study period (approximately 3 months). | The magnitude of concern will be assessed by four levels including not concerned, slightly concerned, concerned, and very concerned. |
| Aspects of physician concern before prescribing SSA treatment | During the whole study period (approximately 3 months). | The magnitude of concern will be assessed by four levels including not concerned, slightly concerned, concerned, and very concerned. |
| Overall patient satisfaction with SSA treatment: satisfied versus dissatisfied with their SSA treatment. | During the whole study period (approximately 3 months). | The patient satisfaction will be categorized as binary variables including satisfied (very satisfied and satisfied) versus dissatisfied (dissatisfied and very dissatisfied). |
| Physician satisfaction with frequency of administration of SSA treatment | During the whole study period (approximately 3 months). | — |
Outcome results
None listed